Antitumor activity of inhibiting SYK kinase with TAK-659, an investigational agent, in DLBCL models.
Jessica J. Huck(Takeda (United States)), Karuppiah Kannan(Takeda (United States)), Matthew Theisen(Dana-Farber Cancer Institute), Mark Manfredi(Millennium Engineering and Integration (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States)), Mengkun Zhang(Millennium Engineering and Integration (United States)), Helen He(Icahn School of Medicine at Mount Sinai), Patrick W. Vincent(Zanzibar University), Steve Tirrell(Takeda (United States)), Jie Yu(KU Leuven), Josephine M. Atienza(Takeda (United States)), Rachael Brake(Takeda (United States)), Suresh K. Balani(Amgen (United States))
Cited by 6
Related Papers
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654
Carbon-dot-supported atomically dispersed gold as a mitochondrial oxidative stress amplifier for cancer treatment
|Nature Nanotechnology|2019|598
A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment
|Nature Medicine|2018|453